TABLE 1.
Laboratory instrumentation and workflow overview
| Condition | Instrumentation or workflow overview for:a |
|||
|---|---|---|---|---|
| WKL | TC | HRMLP | SHSL | |
| Pre-FLA instrumentation | None | None | None | 2 WASP |
| Post-FLA instrumentation | 2 WASP, 1 track line, 3 incubators | 1 WASP, 2 incubators | 2 WASP, 1 track line, 3 incubators | 3 WASP, 2 track lines, 6 incubators |
| Specimen processing | Pre-FLA, 24/7 with 70% of volume processed off-site; post-FLA, 24/7 with 100% volume processed on-site | Pre-FLA, 24/7; post-FLA, 24/7 | Pre-FLA, 24/7; post-FLA, 24/7 | Pre-FLA, 24/7; post-FLA, 24/7 |
| Culture workup | Pre-FLA, 08:00–19:00; post-FLA, 24/7 | Pre-FLA, workup 07:00–00:30; post-FLA, 05:30-02:30 | Pre-FLA, 08:00–17:00; post-FLA, 08:00–23:00 (positive blood cultures: 24/7) | Pre-FLA, 24/7; post-FLA, 24/7 |
| Specimens/collections processed by WASP/FLA (percent of laboratory volume) | Urine, MRSA, ESwab, GBS, body fluid, positive blood culture (87% FLA) | Urine, MRSA, ESwab, respiratory, GAS, body fluid, disc diffusion AST (90% WASP; 81% FLA) | Urine, MRSA, VRE, GAS, CSF, positive blood culture (88% WASP; 80% FLA) | Urine, MRSA, GAS, GBS, body fluid, stool (96% FLA) |
| Segregation algorithms | No | Yes: urine | Yes: urine, MRSA, VRE, MRSA/VRE biplate | Yes: urine, MRSA |
| Years between pre- and post-FLA analysis | 3 | 5 | 8 | 3 |
a
WLK, Willis-Knighton Laboratory; TC, TriCore Reference Laboratories; HRMLP, Hamilton Regional Medicine Laboratory Program; SHSL, Sutter Health Shared Laboratory; WASP, Walk-Away specimen processor; FLA, full laboratory automation; MRSA, screening culture for MRSA; GBS, screening culture for group B Streptococcus; GAS, screening culture for group A Streptococcus; AST, antimicrobial susceptibility testing; VRE, screening culture for VRE; ESwab, specimens collected in ESwab devices; CSF, cerebrospinal fluid.